We recently published a list of 12 Best Growth Stocks to Invest In According to Analysts. In this article, we are going to ...

Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...

Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF ...

Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...

The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...

Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Aggregate cash and cash equivalents and short-term investments were $412.3M and $186.2M at December 31, 2024 and December 31, 2023, ...

Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.

Over the last year, a good number of insiders have significantly increased their holdings in Summit Therapeutics ...